Core Insights - Maikang Bio announced the completion of a multi-hundred million yuan D+ round financing on December 25, with investments from Chengdu Science and Technology Investment, Shenzhen Capital Group, Guosheng Capital, and Linchuang Lanwan [1] Group 1: Financing Details - The funds raised will primarily support the market launch and commercialization of the recombinant shingles vaccine, the Phase III clinical research of the recombinant respiratory syncytial virus vaccine, and the preclinical development of multiple innovative vaccine pipelines and international collaborations [1] Group 2: Company Background - Established in 2016, Maikang Bio is a global biopharmaceutical company focused on the research, development, production, and commercialization of innovative vaccines and novel adjuvants [1] - The company was founded by Dr. Chen Dexiang, a returnee PhD, and has been recognized as a national high-tech enterprise and a specialized and innovative enterprise in Sichuan Province, consistently listed in the GEI China (potential) unicorn enterprises list [1]
迈科康生物宣布完成D+轮融资，用于支持创新疫苗上市及商业化
Cai Jing Wang·2025-12-25 08:39